Glucagon-like peptide-1 (GLP-1)

Overview

Glucagon-like peptide-1 (GLP-1) is an endogenous incretin peptide hormone released from enteroendocrine L-cells, best known for amplifying glucose-stimulated insulin secretion after meals. In normal physiology, GLP-1 acts as a rapid, short-lived signal that links nutrient intake to pancreatic islet function, gastrointestinal motility, and appetite regulation. The native peptide is quickly degraded in circulation by dipeptidyl peptidase-4 (DPP-4), which is why therapeutic GLP-1 receptor agonists (e.g., semaglutide) are engineered for prolonged activity. On PeptideKnow, GLP-1 matters for two reasons. First, it is the biological template for modern obesity and type 2 diabetes drugs. Second, the popularity of GLP-1 receptor agonists has created a complex supply chain for peptide (and peptide-like) active ingredients, including bulk drug substances that are sometimes diverted into unapproved or counterfeit channels. When regulators refer to “GLP-1 receptor agonist bulk drug substances,” they are talking about the upstream materials used to manufacture finished products or compounded preparations—not a consumer product you should ever handle directly.

Mechanism of Action

GLP-1 binds the GLP-1 receptor (GLP-1R), a class B1 G-protein–coupled receptor that primarily signals through Gαs to increase intracellular cAMP. In pancreatic β-cells, this signaling potentiates glucose-dependent insulin secretion; GLP-1 also suppresses glucagon release, slows gastric emptying, and reduces appetite via central and peripheral pathways.

Potential Benefits

• Physiologic incretin signal that enhances glucose-stimulated insulin secretion
• Supports postprandial glucose control via insulin/glucagon modulation
• Contributes to appetite and gastric motility regulation

Research Dosage Notes

The following reflects doses used in published research studies. This is not medical advice.

Native GLP-1 is not typically used as a compounded or consumer peptide because it is rapidly degraded and because clinically used GLP-1 pathway medicines are regulated drug products. If you see ‘GLP-1’ sold as a consumer peptide or as bulk powder, treat it as a high-risk signal that the product is not part of a legitimate supply chain.

Routes of Administration

Read our full Routes of Administration Guide for detailed comparison of all delivery methods.

Amino Acid Sequence

Side Effects & Safety

• Physiologic GLP-1 signaling can slow gastric emptying; drug-induced GLP-1R activation commonly causes nausea and GI symptoms, but those effects depend on specific agonists and dosing.

Pharmacokinetics

Synergistic Compounds

The following compounds have been studied alongside Glucagon-like peptide-1 (GLP-1) for potential complementary or synergistic effects:

Related Peptides

Learn More

References & Further Reading

• Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor2012
• Import Alerts by Publish Date (Import Alert 66-80: Detention Without Physical Examination of GLP-1 Receptor Agonist Bulk Drug Substances)2026